tbuckley/cabot-search huggingface dataset:
Engineering Bioactive Self-Healing Antibacterial Exosomes Hydrogel for Promoting Chronic Diabetic Wound Healing and Complete Skin Regeneration: Erratum
Authors: Chenggui Wang, Min Wang, Tianzhen Xu, Xingxing Zhang, Cai Lin, Weiyang Gao, Huazi Xu, Bo Lei, Cong Mao
Journal: Theranostics (2021)

[This corrects the article DOI: 10.7150/thno.29766.].
Manuscripts Approved for JNCI, January 1 to February 1, 1969
Journal: JNCI Journal of the National Cancer Institute (1969)

Manuscripts Approved for JNCI, January 1 to February 1, 1969 JNCI: Journal of the National Cancer Institute, Volume 42, Issue 3, March 1969, Page 529, https://doi.org/10.1093/jnci/42.3.529 Published: 01 March 1969
A proof-of-concept formative trial evaluating the interest of multiple connected devices for the early detection of hand-foot skin reactions in patients treated with regorafenib therapy (FACET).
Authors: Romain Coriat, Vincent Sibaud, Emmanuelle Dochy, Thibaut Leturgez, Pierre Arvis, Michael Kremliovsky, John A. Reeves, Mario Di Palma
Journal: Journal of Clinical Oncology (2022)

TPS207 Background: Hand-foot skin reaction (HFSR) is a common skin toxicity associated with regorafenib that may lead to drug withdrawal, dose reduction, or drug interruption. Predicting or recognizing early symptoms of HFSR could allow for better care. Digital solutions for ambulatory monitoring of patients provide an opportunity for monitoring and early detection of HFSR in home conditions. Methods: FACET is a phase 4, prospective, open-label, multicenter, interventional trial designed to assess the clinical utility, technical feasibility and usability of a system including a camera, FeetMe Connected insoles for gait assessment, ePRO questionnaires (HFS-14, EQ-5D-5L, FAS and VAS), and educational materials to detect and grade the severity of HFSR. During the study, enrolled patients developing an HFSR will be assigned to the HFSR group and patients without any sign of HFSR, they will be assigned to non-HFSR group. Study registration number at ANSM (French Authority): ID-RCB 2020-A03080-39. Patients will have metastatic colorectal cancer requiring initiation of regorafenib in accordance with clinical practice standard. Other key inclusion criteria are ECOG Performance Status 0-2, ability to understand the instructions and complete the ePRO questionnaires, ability to understand and communicate in French language, familiarity in using mobile communication devices and mobile application software, no previous episode of HFSR or HFS. The primary objective is to explore fit-for-purpose, and usability of the ePRO instruments and the data collecting devices. The primary endpoint is participants’ compliance with data collection measured by ePRO questionnaires completion, use of camera to take images vs expected and number of device days of insoles usage vs expected. Secondary objectives are to characterize variables exhibiting significant associations with development of HFSR. Secondary endpoints include summary statistics of ePRO questionnaires scores at the HFSR worst grade event in the HFSR group vs at 3 weeks in the non-HFSR group; Summary statistics for Feetme Connected insoles variables; Regorafenib dose modifications and treatment discontinuation; Participant’s device daily use to generate data; Participants ability to reach a hotline for technical issues or usability complaints. For HFSR related secondary endpoints, a blinded and independent Preliminary Adjudication Committee (PAC) will retrospectively assign participants to two groups (HFSR vs. no-HFSR) based on a case-by-case blinded assessment. An independent Final Adjudication Committee will compare the PAC assessment and investigators’ assessments done on site. It is planned to include a total of 38 participants from 4 centers. As of September 2021, all sites are open and ready to enroll. Study funded by Bayer.
Council on Physical Therapy
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Reminiscences
Authors: A. Harvey
Journal: BMJ (1875)

Case of Alalacosteon, lc'aldino to Exti-emt A4-5p;-oximatici (f 1,he Rai71i 1se/hii, an dl iven dariazo la/ se,, -i (w/hich/ sitpc;-'auz d) ' )' c'ias ,oi/!i-i/l'5 inpossible.-(Extractfrom Case-Book, August 5th, I844.)AMrs.Wo00(1, aged 38, married, and the m-lother of nine childreni, residing
Definitive chemoradiotherapy for locoregional recurrence of esophageal squamous cell carcinoma patients after radical surgery: Retrospective study.
Authors: Kentaro Harada, Shun Yamamoto, Akihiro Ohara, Mai Itoyama, Yoshitaka Honma, Tairo Kashihara, Koji Inaba, Koshiro Ishiyama, Junya Oguma, Hiroshi Igaki, Hiroyuki Daiko, Ken Kato
Journal: Journal of Clinical Oncology (2022)

314 Background: The prognosis of esophageal squamous cell carcinoma (ESCC) patients with recurrence after radical surgery remains poor, with a median overall survival (OS) of 5-10 months. Locoregional recurrence (LR) have a potential to cure by definitive chemoradiotherapy (dCRT) or surgery. However, there are a few data on clinical outcomes of the patients with LR. We evaluated the efficacy and safety of dCRT for LR after radical surgery retrospectively. Methods: The subjects who had LR after surgery were corrected from medical record between January 2015 and April 2020 in our hospital. LR was defined as recurrence within the regional and supraclavicular lymph nodes after curative surgery. CRT consist of fluoropyrimidine and platinum with radiation at a dose of 50.4-60Gy. Complete response (CR) rate, progression-free survival (PFS), OS, and safety was evaluated. Results: Twenty-five patients who had LR after surgery were analyzed with the median follow-up time of 21.5 (range: 0.47-60.2) months. Patients’ characteristics at the initiation of dCRT were as follows; median age (range): 70 (40-70) years old, male/female: 20 (80%)/5 (20%) patients, PS 0/1/2: 11 (44%)/12 (48%)/ 2 (8%) patients. Chemotherapy regimens were cisplatin and 5-fluorouracil in 23 (92%) patients, nedaplatin and 5-fluorouracil in 1 (4%) patient, and S-1 in 1 (4%) patient. Radiation doses were 60 Gy in 24 (96%) patients and 50.4 Gy in 1 (4%) patient. CR was achieved in 13 (53%) patients. The median PFS was 9.7 (95%CI: 5.6-NA) months, and the median OS was 28.8 (95%CI: 21.2-NA) months. The one-year survival rate was 78.7 (95%CI: 56.1-90.6) % and the three-years survival rate was 25.9 (95%CI: 5.1-54.1) %. Grade 3 or higher adverse events were observed in 3 (12%) patients of neutropenia, in 3 (12%) patients of leukopenia, and in 2 (8%) patients of febrile neutropenia. Treatment-related death due to febrile neutropenia was observed in 1 (4%) patient. No patient presented with severe late toxicity after dCRT. Conclusions: In this study, dCRT for LR after surgery was tolerable and promising efficacy with curative intent.
Cardiovascular therapeutics: A new potential for anxiety treatment?
Authors: Kristina Repova, Silvia Aziriova, Kristina Krajcirovicova, Fedor Simko
Journal: Medicinal Research Reviews (2022)

Abstract Besides the well‐recognized risk factors, novel conditions increasing cardiovascular morbidity and mortality are emerging. Undesirable emotions and behavior such as anxiety and depression, appear to participate in worsening cardiovascular pathologies. On the other hand, deteriorating conditions of the heart and vasculature result in disturbed mental and emotional health. The pathophysiological background of this bidirectional interplay could reside in an inappropriate activation of vegetative neurohormonal and other humoral systems in both cardiovascular and psychological disturbances. This results in circulus vitiosus potentiating mental and circulatory disorders. Thus, it appears to be of utmost importance to examine the alteration of emotions, cognition, and behavior in cardiovascular patients. In terms of this consideration, recognizing the potential of principal cardiovascular drugs to interact with the mental state in patients with heart or vasculature disturbances is unavoidable, to optimize their therapeutic benefit. In general, beta‐blockers, central sympatholytics, ACE inhibitors, ARBs, aldosterone receptor blockers, sacubitril/valsartan, and fibrates are considered to exert anxiolytic effect in animal experiments and clinical settings. Statins and some beta‐blockers appear to have an equivocal impact on mood and anxiety and ivabradine expressed neutral psychological impact. It seems reasonable to suppose that the knowledge of a patient's mood, cognition, and behavior, along with applying careful consideration of the choice of the particular cardiovascular drug and respecting its potential psychological benefit or harm might improve the individualized approach to the treatment of cardiovascular disorders.
Assessment of dietary quality in patients on surveillance for colorectal cancer (CRC) using a computerized food frequency questionnaire (FFQ).
Authors: Rishi Jain, Jessie Rachel Panick, Elizabeth A. Handorf, Karen Vincek, Kara Stromberg, Leah Fein, Nicole Ross, Jordan Senchak, Jessica R Bauman, Michael J. Hall, Crystal S. Denlinger, Carolyn Y Fang
Journal: Journal of Clinical Oncology (2022)

66 Background: Poor dietary patterns are clearly implicated in the pathogenesis of CRC and are increasingly associated with worsened CRC outcomes, including a higher risk of cancer recurrence and mortality. We evaluated the use of a novel computerized FFQ technology to assess dietary patterns in patients with CRC who were undergoing cancer surveillance. Methods: We recruited patients with stage I-III CRC who had completed curative intent therapy at least 1 year but no more than 5 years prior to enrollment. Dietary assessment was conducted using a computerized FFQ (VioScreen) either in clinic or at home. Dietary quality was defined by the Healthy Eating Index (HEI) 2015 score which was calculated automatically by the FFQ technology. Statistical significance was determined using Pearson correlation and analysis of variance (ANOVA). Results: Twenty patients (14 colon, 6 rectal; 12 male, 8 female; median age 66 [49-80]; median 3 years from diagnosis) were recruited between 10/2020-9/2021. Fourteen patients did FFQ remotely and 6 in-person. Nineteen patients were white/non-Hispanic. All received surgery, 20% radiation (all rectal) and 75% chemotherapy. Mean HEI 2015 total and sub-scores are shown in the table. There were significant differences in dietary quality by age &lt;65 vs ≥65 (HEI 58.3 vs. 72.6, p=0.025), body-mass-index (BMI) normal/overweight vs. obese (HEI 72.4 vs. 58.6, p=0.033), and marital status of married vs non-married (HEI 61.7 vs. 76.7, p=0.032). There were no differences in dietary quality by level of education, tumor site (colon vs. rectal) or gender. There was a significant negative correlation with increased time since diagnosis and lower dietary quality (r= -0.67, p&lt;0.001). Conclusions: Dietary patterns can be determined using a computerized FFQ in patients with CRC on surveillance both remotely and in-person. This population has a wide range of dietary patterns with particularly low scores in whole grain, fatty acid, sodium and saturated fat. Patients who are older, non-obese, non-married, and closer to completion of cancer therapy have higher dietary quality scores. Future studies of integrating a computerized FFQ into cancer care will determine whether personalized interventions targeting specific dietary patterns can improve diet quality.[Table: see text]
THE TREATMENT OF PUERPERAL ECLAMPSIA
Journal: BMJ (1905)

T~E t.re~tment of puerperal eclampsi~ is one of the burning questŸ in obstetrics ~t the present time, a.nd I suppose tha.t during the 1)ast few yea.rs more ha, s been said ~nd wriiten a.bout ir t-ha.nanv other connected with the management of childbirth.But it is •lot my l)resent intent.ion to enter upon ah exhaus~ix'e eritieism of all the methods of treating this disease which a.re a.t present in vogue, but rather to make a few remarks asa contribution to the diseussion of Dr.I 91 5Iaouire's paper.In the first place, then, what do we know as to the nature of the eondition which we are so often called upoa to t.reat?Until quite recent, times I could hardly have deseribed ir as a disease but rat.her as a complex of symptoms.But sinee the publieation of the investigations of Lubarsch and Sehmorl ir is generally recognised tha.t this eondition is eharaeterised by eertain de¡ pathologieal and anatomical ehanges, consisting chiefly in degenerations and neeroses of the tissue eells, aecompanied by hamorrhages and t hrombosis, espeeially in the smallest veins.These ehanges whieh are always to be., found in t.he most important organs of the body~the brain, the heart, the liver, and the kidneys~are the, essentŸ features of this disease and not the symptoms, By SIR W.
TCT-625 Clinical impacts of Beta-blockers in patients following acute myocardial infarction without heart failure or left ventricular dysfunction(left ventricular ejection fraction&gt;40%)
Authors: Hanbit Park, Minsoo Kim, Sang Yong Om, Yong-Hoon Yoon, Sang-Cheol Cho, Osung Kwon, Ungjeong Do, Kyusup Lee, Do-yoon Kang, Cheol Hyun Lee, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2017)
Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability
Authors: Xiaoyu Liu, Zhi Li, Zhongmin Wang, Fei Liu, Linling Zhang, Jingjing Ke, Xu Xu, Yuefang Zhang, Yiting Yuan, Tao Wei, Qungang Shan, Yingjie Chen, Wei Huang, Jie Gao, Nan Wu, Fuliang Chen, Lunquan Sun, Zilong Qiu, Yuezhen Deng, Xiaojing Wang
Journal: Cancer Research (2022)

ARID1A is a key mammalian SWI/SNF complex subunit that is mutated in 5% to 11% of lung cancers. Although recent studies have elucidated the mechanism underlying dysregulation of the switch/sucrose non-fermentable (SWI/SNF) complexes in cancers, the significance of ARID1A loss and its implications in lung cancers remain poorly defined. This study investigates how ARID1A loss affects initiation and progression of lung cancer. In genetically engineered mouse models bearing mutant Kras and a deficient Trp53 allele (KP), ARID1A loss (KPA) promoted lung tumorigenesis. Analysis of the transcriptome profiles of KP and KPA tumors suggested enhanced glycolysis following ARID1A loss, and expression of the glycolytic regulators Pgam1, pyruvate kinase M (Pkm), and Pgk1 was significantly increased in ARID1A-deficient lung tumors. Furthermore, ARID1A loss increased chromatin accessibility and enhanced hypoxia-inducible factor-1α (HIF1α) binding to the promoter regions of Pgam1, Pkm, and Pgk1. Loss of ARID1A in lung adenocarcinoma also resulted in loss of histone deacetylase 1 (HDAC1) recruitment, increasing acetylation of histone-4 lysine at the promoters of Pgam1, Pkm, and Pgk1, and subsequently enhancing BRD4-driven transcription of these genes. Metabolic analyses confirmed that glycolysis is enhanced in ARID1A-deficient tumors, and genetic or pharmacologic inhibition of glycolysis inhibited lung tumorigenesis in KPA mice. Treatment with the small molecule bromodomain and extraterminal protein (BET) inhibitor JQ1 compromised both initiation and progression of ARID1A-deficient lung adenocarcinoma. ARID1A negatively correlated with glycolysis-related genes in human lung adenocarcinoma. Overall, ARID1A loss leads to metabolic reprogramming that supports tumorigenesis but also confers a therapeutic vulnerability that could be harnessed to improve the treatment of ARID1A-deficient lung cancer.This study links ARID1A loss with enhanced glycolysis in lung cancer and demonstrates the preclinical efficacy of BET inhibitor therapy as a strategy to combat tumor growth.
Body mass index, obesity, and cachexia vs survival in chronic heart failure: Results from the ELITE 2 study Stefan D. Anker, Constantinos H. Davos, Darrel Francis, Robert Segal, Emanuela Santoro, Philip A. Poole-Wilson, Bertram Pitt, Andrew J. S. Coats. National Heart &amp; Lung Institute, London, United Kingdom, Franz-Volhard-Klinik, Charit� Campus Berlin-Buch, Berlin, Germany
Journal: Journal of the American College of Cardiology (2001)
318O Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients
Authors: D.J. Pinato, A. Zambelli, A. Bertuzzi, A. Marrari, N. Saoudi-Gonzalez, O. Mirallas, M. Galazi, D. Generali, S. Grisanti, C. Tondini, A. Prat, J. Tabernero, R. Mesia, R. Salazar, A. Sureda, M. Franchi, L. Chiudinelli, D.G. Illescas, M. Libertini, A. Gennari
Journal: Annals of Oncology (2020)
MEDICAL LITERATURE ABSTRACTS
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SpeciesRax: A Tool for Maximum Likelihood Species Tree Inference from Gene Family Trees under Duplication, Transfer, and Loss
Authors: Benoit Morel, Paul Schade, Sarah Lutteropp, Tom A Williams, Gergely J Szöllősi, Alexandros Stamatakis
Journal: Molecular Biology and Evolution (2021)

Species tree inference from gene family trees is becoming increasingly popular because it can account for discordance between the species tree and the corresponding gene family trees. In particular, methods that can account for multiple-copy gene families exhibit potential to leverage paralogy as informative signal. At present, there does not exist any widely adopted inference method for this purpose. Here, we present SpeciesRax, the first maximum likelihood method that can infer a rooted species tree from a set of gene family trees and can account for gene duplication, loss, and transfer events. By explicitly modeling events by which gene trees can depart from the species tree, SpeciesRax leverages the phylogenetic rooting signal in gene trees. SpeciesRax infers species tree branch lengths in units of expected substitutions per site and branch support values via paralogy-aware quartets extracted from the gene family trees. Using both empirical and simulated data sets we show that SpeciesRax is at least as accurate as the best competing methods while being one order of magnitude faster on large data sets at the same time. We used SpeciesRax to infer a biologically plausible rooted phylogeny of the vertebrates comprising 188 species from 31,612 gene families in 1 h using 40 cores. SpeciesRax is available under GNU GPL at https://github.com/BenoitMorel/GeneRax and on BioConda.
Deviation from the precisely timed age-associated patterns revealed by blood metabolomics to find CRC patients at risk of relapse at the CRC diagnosis.
Authors: Sheeno P. Thyparambil, Xiurui Zhu, Yani Zhang, Hui Sun, Junjie Peng, Sanjun Cai, Yaqi Li, Chen Fu, Pingping Bao, Shiying Hao, Zhen Li, Yun Ding, Xiaoming Yao, Wei-Li Liao, Robert Heaton, Zhi Han, Lu Tian, James Schilling, Karl G. Sylvester, Xuefeng Ling
Journal: Journal of Clinical Oncology (2022)

206 Background: Human serum metabolome profiles have been analyzed to explore the molecular changes that occur with aging. We hypothesized that deep metabolic profiling of sera with different ages would allow the identification of distinct metabolic chronologic patterns as a normal biological baseline to study personal aging. We further hypothesized that metabolic assessment of this chronologic deviation, resulting from advanced precancerous lesion (APL) and stage I/II/III CRC, from the normal reference baseline, would be instrumental for prognosis of relapse revealing underlying pathophysiology. Methods: A cohort of normal (n=3,616, training; n=1,170, testing), 631 advanced adenoma, 1,019 stage I, 404 stage II and 417 stage III serum samples were assembled. Innovative global LCMS metabolomic production were applied to deep profile these subjects. Identification of the age-associated molecular patterns in normal subjects, modeled with an elastic net algorithm, established the reference baseline to mirror a metabolic clock. CRC associated deviation from the precise chronologically paced metabolic patterns was quantified to associate the clinical endpoints of relapse, OSF and PFS, and to identify the tightly associated metabolic pathways. Results: We observed that for those CRCs, the predicted metabolic age can differ from the chronological age with consistent variations, resulting “older” or “younger” metabolic age subgroup in reference to the chronological age. Significant disruptions from the normal baseline were observed in CRCs patients, and consistent stage specific patterns were observed. Outlier, “Older” or “younger” metabolic age subgroup, CRC patients were found with significant future relapse enrichment. Predictive models were derived to case find the patients at risk of future relapse at the CRC diagnosis timepoint. Conclusions: Deviations from the meticulously timed metabolic aging patterns may provide utility to allow prognosis of future clinical endpoints of relapse and overall survival. Close examination of the underlying metabolic pathways, associated with CRC stage specific metabolic patterns, disrupting the baseline ageotypes, not only may improve the sensitivity and specificity of prognostic tests of CRC relapse, but also shed new insights into CRC therapeutics.
A cross-sectional analysis of the relationship between hormone replacement therapy and coronary artery calcification Amy M. Gallagher, Enrique F. Schisterman, Howard C. Lewin, Sean W. Hayes, John D. Friedman, Romalisa S. Miranda, Arlene Ledesma, Daniel S. Berman. Cedars-Sinai Medical Center, Los Angeles, CA
Journal: Journal of the American College of Cardiology (2001)